What We're Reading: Page 223
Industry reads hand-picked by our editors
Sep 05, 2019
-
The Wall Street Journal
Texas Doctor Stephen M. Hahn Is a Top Contender to Head FDA
-
Reuters
Novartis sees cell, gene therapy reaching up to 15% of sales in midterm
-
The New York Times
Johns Hopkins Opens New Center for Psychedelic Research
-
The Boston Globe
Did a biotech exec crib a New Yorker cartoon?
Sep 04, 2019
Sep 03, 2019
-
Barron's
mRNA Is the Next Frontier in Treating Disease. But Will It Work?
-
The Wall Street Journal
Ohio Attorney General Seeks Delay of Landmark Opioid Trial
-
The Washington Post
Rare childhood disease prompts family to seek cure
-
MarketWatch
AstraZeneca shares hit record after Farxiga study
Aug 30, 2019
-
The Wall Street Journal
Proposed Opioid Deal With Purdue Drawing Pushback From States
-
Bloomberg
Juul Seizure Reports Prompt FDA Probe into E-Cigarettes
-
Endpoints News
On track for first autoimmune drug approval, Bing Yao steers AstraZeneca spinoff to $150M IPO
-
STAT
Vaccine coalition unveils ambitious plan to immunize 300 million children
Aug 29, 2019
-
The Wall Street Journal
New Concerns Emerge About Long-Term Antidepressant Use
-
Associated Press
Pinterest to direct vaccine-related searches to health orgs
-
Reuters
Roche immunotherapy Tecentriq gains European approval for breast cancer
Aug 28, 2019
-
The New York Times
Johnson & Johnson's Brand Falters Over Its Role in the Opioid Crisis
-
Vantage
Six burning Otezla questions
-
Kaiser Health News
Beset by lawsuits and criticism in U.S., opioid makers eye new market in India
-
The Oklahoman
Cannabisville, Oklahoma: The ZIP code with most business licenses
Previous
